retatrutide nejm 2023 obesity trial ly3437943 phase 2 triple agonist Research Guide: What the Data Reported (2026) Retatrutide vs Semaglutide: Triple vs – Retatrutide Statistics 2026: Phase 2

Understanding these levels helps guide dietary choices or supplementation needs

Studies show that participants receiving placebo often lose 2-5% of body weight through increased attention to diet, regular weigh-ins, and behavioral support provided by trial participation

Keep enough time for processing, travel, and any clinical questions that may need clarification

10.1002/mnfr.201300729 251 MusanteL

Whilst they affect gut function by slowing gastric emptying and influencing motility, their gastrointestinal side effectsincluding nausea, diarrhoea, constipation, and bloatingmay overlap with or potentially worsen existing IBS symptoms